Montelukast and frequency of exacerbations of asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Montelukast in exercise-induced asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 263s Year: 2006
Oral montelukast in patients with acute severe asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Montelukast as add-on therapy in severe noninfectious COPD exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003
Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018
Montelukast and budesonide therapy of asthmatic patients suffering from chronic cough Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Difficult-to-treat and severe asthma Source: Breathe 2014; 10: 91-94 Year: 2014
Thermoplasty for severe asthma Source: ERS Skills Course 2016 Year: 2016
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009